Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Intravenous SelK2 in Asthma and COPD
2020-001027-13Phase 2Unknown
- Sponsor
- Tetherex Pharmaceuticals
- Start
- May 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of SelK2 in asthma and chronic obstructive pulmonary disease (COPD) (4 arms), sponsored by Tetherex Pharmaceuticals. Primary endpoints: Airway responses following allergen challenge in asthma (Part 1), Safety of SelK2 in asthma (Part 1) and 2 more. Status: unknown.
02
Drugs
SelK2
03
Conditions
asthmachronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2020-001027-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001027-13.